Clinical Trial Update: Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria

View source ↗

Summary

The clinical trial update indicates that compassionate-use access to the pozelimab and cemdisiran combination therapy for Paroxysmal nocturnal hemoglobinuria is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Cemdisiran (cemdisiran)
• Pozelimab

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Status: NO_LONGER_AVAILABLE